This paper is in the following e-collection/theme issue:

Psychotic Disorders (160) Smoking Cessation (556)

Published on in Vol 7, No 2 (2020): February

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16524, first published .
Brief, Web-Based Interventions to Motivate Smokers With Schizophrenia: Randomized Controlled Trial

Brief, Web-Based Interventions to Motivate Smokers With Schizophrenia: Randomized Controlled Trial

Brief, Web-Based Interventions to Motivate Smokers With Schizophrenia: Randomized Controlled Trial

Authors of this article:

Mary F Brunette1, 2 Author Orcid Image ;   Joelle C Ferron2 Author Orcid Image ;   Susan R McGurk3 Author Orcid Image ;   Jill M Williams4 Author Orcid Image ;   Amy Harrington5 Author Orcid Image ;   Timothy Devitt6 Author Orcid Image ;   Haiyi Xie1 Author Orcid Image
Article Authors Cited by (22) Tweetations (1) Metrics

    Original Paper

    1Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock, Concord, NH, United States

    2Dartmouth-Hitchcock, Concord, NH, United States

    3Boston University, Boston, MA, United States

    4Rutgers, New Brunswick, NJ, United States

    5University of Massachusetts, Worcester, MA, United States

    6Thresholds, Inc, Chicago, IL, United States

    Corresponding Author:

    Mary F Brunette, MD

    Geisel School of Medicine at Dartmouth

    Dartmouth-Hitchcock

    2 Pillsbury St

    Concord, NH, 03301

    United States

    Phone: 1 603 229 5419

    Email: Mary.F.Brunette@Dartmouth.edu


    Background: In-person motivational interventions increase engagement with evidence-based cessation treatments among smokers with schizophrenia, but access to such interventions can be limited because of workforce shortages and competing demands in mental health clinics. The use of digital technology to deliver interventions can increase access, but cognitive impairments in schizophrenia may impede the use of standard digital interventions. We developed an interactive, multimedia, digital motivational decision support system for smokers with schizophrenia (Let’s Talk About Smoking). We also digitalized a standard educational pamphlet from the National Cancer Institute (NCI Education). Both were tailored to reduce cognitive load during use.

    Objective: We conducted a randomized trial of Let’s Talk About Smoking versus NCI Education to test whether the interactive motivational intervention was more effective and more appealing than the static educational intervention for increasing use of smoking cessation treatment, quit attempts, and abstinence among smokers with schizophrenia, accounting for the level of cognitive functioning.

    Methods: Adult smokers with schizophrenia (n=162) were enrolled in the study from 2014 to 2015, randomly assigned to an intervention condition, and assessed in person at 3- and 6-month follow-ups. Interventions were delivered on a laptop computer in a single session. All participants had access to standard, community-delivered cessation treatments during follow-up. Multivariate models were used to evaluate outcomes.

    Results: Treatment initiation outcomes were not different between intervention conditions (27/84 [32%] for Let’s Talk About Smoking vs 36/78 [46%] for NCI Education; odds ratio [OR] 0.71 [95% CI 0.37-1.33]); 38.9% (63/162) of participants initiated treatment. Older age (OR 1.03 [95% CI 1.00-1.07]; P=.05), higher education (OR 1.21 [95% CI 1.04-1.41]; P=.03), and fewer positive symptoms (OR 0.87 [95% CI 0.80-0.96]; P=.01) predicted cessation treatment initiation, whereas level of cognition did not. The mean satisfaction and usability index score was higher for Let’s Talk About Smoking versus NCI Education (8.9 [SD 1.3] vs 8.3 [SD 2.1]; t120.7=2.0; P=.045). Quit attempts (25/84, 30% vs 36/78, 46%; estimate [Est]=−0.093, SE 0.48; P=.85) and abstinence (1/84, 1% vs 6/78, 7%; χ21=3.4; P=.07) were not significantly different between intervention conditions. Cognitive functioning at baseline (Est=1.47, SE 0.47; P=.002) and use of any behavioral or medication cessation treatment (Est=1.43, SE 0.47; P=.003) predicted quit attempts with self-reported abstinence over the 6-month follow-up.

    Conclusions: The interactive, multimedia intervention was not more effective than the static, text-based intervention among smokers with schizophrenia. Both tailored digital interventions resulted in levels of treatment engagement and quit attempts that were similar to findings from previous studies of in-person interventions, confirming the potential role of digital interventions to educate and motivate smokers with schizophrenia to use cessation treatment and to quit smoking. These findings indicate that additional cessation treatment is needed after brief education or motivational interventions, and that cessation treatment should be adjusted for people with cognitive impairment.

    Trial Registration: ClinicalTrials.gov NCT02086162; https://clinicaltrials.gov/show/NCT02086162

    JMIR Ment Health 2020;7(2):e16524

    doi:10.2196/16524

    Keywords

    schizophrenia; smoking; tobacco; technology; digital; motivational interviewing; education; cognition 


    Background

    Clinics serving people with schizophrenia aim to provide interventions for schizophrenia and the common comorbidities associated with this disease. Cigarette smoking, for example, is thrice more likely to occur in people with schizophrenia than in the general population [1,2] and leads to disparate morbidity from smoking-related diseases and early mortality [3]. However, workforce shortages are a challenge for community clinics in the United States [4,5] and interfere with the ability to provide the array of needed interventions for smoking. In addition, treatment providers experience competing demands and may lack clinical expertise for providing tobacco-related interventions [6,7]. Deploying digital tools to deliver behavioral interventions to patients is one way to improve the capacity for behavioral interventions.

    People with schizophrenia and other severe mental illnesses are increasingly using digital technology and are interested in receiving health and mental health interventions via their devices [8-10]. However, people in this group typically have cognitive impairments and distracting symptoms that impede the use of standard digital tools that have complex design features and lower levels of usability [11-14]. To address this problem, we have designed digital tools with evidence-based content that can be easily used by people with cognitive impairments and easily implemented in treatment settings where smokers with schizophrenia receive services [15,16]. Other researchers are also beginning to design and pilot test smartphone apps for smoking cessation in this population [17-19].

    One potential purpose for digital tools in clinics may be to educate and motivate a user for medical treatments. A growing body of literature indicates that cessation medications with behavioral interventions are safe among people with schizophrenia [20,21] and increase the probability of cessation [22-24]. Specifically, cognitive behavioral therapy, motivational counseling, and supportive counseling combined with nicotine replacement therapy, bupropion, or varenicline have been shown to improve cessation outcomes; behavioral interventions with varenicline have resulted in the highest rates of abstinence [20-24]. However, misperceptions about cessation treatment may impede their utilization [25-27]. Single-session [28,29] and multiple-session [30,31] in-person motivational and educational interventions for patients may overcome this problem, increasing treatment initiation and quit attempts among smokers with schizophrenia and other severe mental illnesses. Whether interventions delivered with digital technology can similarly increase cessation treatment initiation and quit attempts among people with schizophrenia has not yet been tested.

    Objectives

    We conducted a randomized trial of a brief, interactive, multimedia intervention (Let’s Talk About Smoking) compared with a static, computerized version of an education pamphlet from the National Cancer Institute (NCI) among smokers with schizophrenia. Both interventions were tailored to reduce cognitive load on the user. We hypothesized that the rate of treatment initiation and cessation behaviors would be higher among participants assigned to Let’s Talk about Smoking than among those assigned to NCI Education. In addition, we hypothesized that the level of cognitive ability would moderate participants’ use of cessation treatment and ability to achieve abstinence.


    Enrollment and Study Participants

    Potentially eligible smokers with schizophrenia were recruited via flyers in waiting rooms and by clinician invitation from mental health treatment programs in New Jersey, Massachusetts, and Illinois from 2014 to 2015. We enrolled English-speaking, daily smokers with schizophrenia spectrum disorders, aged 18 to 65 years, who were psychiatrically stable in outpatient treatment for mental illness (Brief Psychiatric Rating Scale (BPRS) score <70) [32] and who were willing and able to give informed consent. Smokers were excluded if they had recently (past month) used evidence-based smoking cessation treatment (indicating the participant was already motivated to use treatment), were pregnant or nursing, or had current untreated alcohol or drug dependence diagnoses. Computer experience was not required. As the intervention was designed to increase motivation for cessation, intention to quit smoking was not required. In total, 184 participants were consented and assessed for eligibility; 173 were eligible, 162 were randomized and received study interventions, and 145 (89.5% of those randomized) completed the 6-month follow-up (see Figure 1 for participant flow).

    ‎
    Figure 1. Study flow. *Participants missed 3-month visit but completed the 6-month visit. NCI: National Cancer Institute.

    Study Procedures

    After obtaining informed consent through reading the consent form aloud and answering questions, research staff conducted baseline assessments in 2 in-person meetings, with neurocognitive assessments obtained at the second meeting to reduce fatigue. Within 2 weeks of consent, eligible participants were randomized 1:1 to receive one of the interventions using computer-generated random order lists in blocks of 8, stratified by study site, with study participant allocation provided via preprepared, individual envelopes that were unsealed by research staff at the time the participant arrived for the intervention visit. Participants were not informed of the details of the study hypothesis and did not know which comparator was hypothesized to outperform the other.

    Using a standard protocol, research staff oriented participants to their assigned intervention, which was provided in a clinic office on a laptop computer with a mouse. They provided brief training, coaching, and assistance if needed. After completing either intervention, participants completed a computerized satisfaction questionnaire (to reduce social desirability bias) and received referral information to locally available cessation treatment (cessation medications and cessation counseling) by clinicians who were trained in providing evidence-based cessation treatment to people with serious mental illnesses (SMIs). At 3 and 6 months, research interviewers who were blinded to intervention assignment assessed participants in person for the use of verifiable cessation treatment (main outcome), smoking characteristics, self-reported quit attempts (days of abstinence), and biologically verified abstinence (secondary outcomes; see Measures section). Research staff provided participants US $50 on completion of each assessment visit. Data quality was monitored throughout the study by the first author, the research data team, and a Data Safety and Monitoring Board. The study was reviewed and monitored by the Dartmouth Committee for the Protection of Human Subjects and the Institutional Review Boards of research sites.

    Intervention Conditions

    Web-Based Motivational Intervention

    Let’s Talk About Smoking is a Web-based intervention tailored for smokers with severe mental illnesses and designed to increase motivation to quit smoking using evidence-based treatment. The development of the intervention’s content and interface involved extensive input from the intended users and has been described previously [15]. The program is linear, modularized, and interactive, taking 30 to 90 min to complete. Users choose a video host who identifies him/herself as an ex-smoker with mental illness and guides users through modules, each with assessments and exercises used in motivational interviewing and health decision aid systems [33,34]. In module 1 (assessment/feedback), users respond to questions and receive personalized feedback about the personal, financial, and health impact of smoking. In module 2 (quit intention), change decisions are facilitated by cessation treatment information and exercises, including creation of a personalized pros and cons list. Module 3 (education about cessation treatments, feedback, and referral) provides selectable quit story videos as well as text and video information about cessation treatments, including the benefits of combined behavioral counseling with pharmacotherapy. A personalized report highlights the desire to quit, treatment choices, and referral information. The developers and their institutions were listed at the end of the intervention.

    By developing the intervention interface and content with iterative user feedback, we ensured that the intervention was easy to use among people with the symptoms and cognitive impairments associated with psychotic disorders [15]. We previously showed that the decision support system was similarly effective among smokers with high and low levels of education, cognitive function, and symptom distress [35]. The intervention content remained constant during the trial.

    Computerized National Cancer Institute Patient Education

    Participants assigned to NCI Education received a computerized version of the NCI patient educational handout [36], which provides information about risk factors and protective factors for cancer and other smoking-related diseases, quitting smoking as a prevention factor, and smoking cessation treatments (both counseling and drug treatments, including nicotine replacement therapy, bupropion, and varenicline). This static intervention was delivered by a laptop computer in a format similar to Let’s Talk About Smoking: large black font on a white background with no distracting images; one concept per page in a short paragraph or bulleted sentences. Automated audio, which read the content to users, could be turned on if the user wished. The publisher of the pamphlet, the NCI, was named as sponsor of the pamphlet in standard text in the beginning and at the end of the intervention.

    Measures

    Demographics, History, and Diagnosis

    Demographics and smoking history were assessed with a structured, in-person interview. Physician-completed Diagnostic and Statistical Manual, Fourth Edition, Text Revision, psychiatric and substance use disorder diagnoses were obtained from clinic chart review.

    Mental Health Symptoms

    Trained research staff assessed psychiatric symptom severity at baseline with the BPRS [32], a widely used symptom scale for symptoms of mental illness. The scale includes five subscales that measure positive psychosis symptoms, negative psychosis symptoms, depression, disorganized symptoms, and activation [37].

    Smoking Characteristics

    Research staff assessed all participants for the level of nicotine dependence with the Fagerström Test for nicotine dependence at baseline and at 3 and 6 months [38-40].

    Motivation for Cessation and Treatment

    We assessed participants for their stage of change for quitting smoking with the single question, “Are you seriously thinking about quitting?” [41]. We also assessed attitudes about using cessation treatment with an adapted Treatment Motivation Scale-Revised, a 23-item scale assessing attitudes about using treatment based on self-determination theory [42]. This scale has five additive subscales that assess perceptions of reasons for treatment, including external motivation (range 4-20), introjected motivation (range 2-10), intrinsic motivation (range 7-35), lack of confidence in using treatment (range 4-20), and relatedness in treatment (range 7-35) [43].

    Primary Outcome—Confirmed Use of Smoking Cessation Treatment and Quit Attempts

    Blinded assessors completed a structured interview to assess all self-reported use of cessation treatment (including nicotine replacement therapy) at any time during each past 3-month period. The use of cessation treatment was confirmed via clinic record review, clinician confirmation, and viewing medications and nicotine replacement at the assessment. The use of cessation treatment and quit attempts were expected to directly result from the use of the study interventions.

    Secondary Outcome—Abstinence

    At the follow-up assessment visits, the self-reported, past week of abstinence from smoking was verified with expired carbon monoxide less than 9 ppm (Smokelyzer Breath Carbon Monoxide Monitor; Bedfont Scientific) [44,45]. In addition, any self-reported quit attempts with abstinence during the treatment period were captured with the Timeline Follow-Back method [46-48]. With this method, trained research staff assessed participants for the amount of smoking and other tobacco product use each day, going back week-by-week over the past 3 months using a calendar to cue memories of smoking and abstinence. The Timeline Follow-Back method has been shown to be reliable and valid in the general population [48] and in people with severe mental illnesses [49]. Abstinence was identified as a secondary outcome that would rely on the use of additional cessation medication and behavioral cessation treatment.

    Intervention Satisfaction, Usability, and Likeability

    Participants completed the Perceived Usefulness and Ease of Use Scale, an adapted 15-item semiqualitative instrument [50] to obtain perceptions of usability and satisfaction with the intervention.

    Cognition

    We assessed cognition at baseline with a battery comprised of the following 6 standard neuropsychological tests that measure cognitive functions typically impaired in schizophrenia and thought to be important for engagement and success in smoking cessation treatment (Multimedia Appendix 1). We assessed sustained attention (Continuous Performance Test, dependent variable: d’) [51], verbal learning (Hopkins Verbal Learning Test; dependent variable: total recall trials 1-3; t score from mean of the three trials)[52,53], processing speed (Trail Making Test Part A; dependent variable: seconds to completion) [54], and, because of the likelihood of important relationships of nicotine abstinence and the prefrontal cortex [55-57], we assessed cognitive flexibility (Trail Making Test Part B: dependent variable: seconds to completion) and inhibitory control (Delis-Kaplan Executive Functioning System Color-Word Interference Test; dependent variable: seconds to completion on word reading, color reading, and color-word interference trials) [58]. The mean of a participant’s normative scores was used as a composite cognition score. Composite scores were not computed for people who had one or more missing test score.

    We also measured word recognition at baseline, calculated from a demographically based index of premorbid intelligence (fourth edition of the Wide Range Achievement Test Reading subtest) [59]. Performance on this test is relatively preserved in people with schizophrenia [60], providing an index of premorbid intellectual function.

    Statistical Analyses

    We used chi-square tests and t tests to assess between-group differences at baseline. We then assessed dichotomous outcomes between intervention groups with logistic regressions (eg, treatment use) [61]. For count outcome variables with a high proportion of zeros and positive skewness (eg, days of abstinence), negative binomial models were used. Modeling began with bivariates and progressed to multivariates using variables providing P<.10 in bivariate models, adjusting for gender and years of education. In the multivariate model predicting any abstinence, the total mean cognitive battery score was used to avoid collinearity among the cognitive function scores. Missing observations for the primary outcome, cessation treatment utilization, were set as missing. Missing observations for the secondary outcome, abstinence, were set as smoking (nonabstinent). Analyses were conducted with SAS version 9.4 (SAS Institute, Cary, North Carolina).


    Overview

    Participants are described in Multimedia Appendix 1. The group included 162 smokers with schizophrenia, with a mean age of 45.91 years (SD 11.32). Two-thirds were male (108/162, 66.7%), more than half identified as black (86/162, 53%). The group was moderately symptomatic (BPRS mean score 41.06, SD 11.11) and reported a mean of 11.12 (SD 13.69) hospitalizations for psychiatric treatment over their lifetimes, demonstrating long-term severe mental illness. Participants smoked an average of 14.56 cigarettes per day (SD 10.59). A low proportion (8.02%) of participants were motivated to quit smoking, and the level of motivation to use cessation treatment was generally low, and it was lowest in perceived external sources of motivation. The group demonstrated moderate cognitive impairments, as expected among people with schizophrenia. Characteristics were not significantly different between participants in the Let’s Talk About Smoking and NCI Education conditions.

    Primary Outcome

    As shown in Table 1, more than one-third (63/162, 38.9%) of all participants used any verifiable cessation treatment during the 6-month follow-up period, and cessation treatment use was not different between intervention groups (27/84, 32.1% of Let’s Talk About Smoking vs 36/78, 46.2% NCI Education; odds ratio [OR] 0.71 [0.37-1.33]; P=.28).

    Table 1. Confirmed cessation behaviors over 6-month follow-up.
    Cessation behaviorsTotal sample (N=162)Let’s Talk About Smoking (N=84) National Cancer Institute Education (N=78)
    Verified use of cessation treatment, n (%)

    		Met with doctor to discuss cessation72 (44.4)37 (44)35 (45)

    		Nicotine replacement therapy34 (20.9)18 (21)16 (21)

    		Bupropion7 (4.3)6 (8)1 (1)

    		Varenicline3 (1.9)0 (0)3 (4)

    		Individual cessation counseling35 (21.6)16 (19)19 (24)

    		Group cessation counseling15 (9.3)7 (8)8 (10)

    		Cessation counseling and medication21 (13.0)12 (14)9 (11)

    		Started any treatment63 (38.9)27 (32)36 (46)
    Self-reported or verified use of cessation treatment, n (%)

    		Met with doctor to discuss cessation92 (56.8)44 (56)48 (57)

    		Nicotine replacement therapy52 (32.1)24 (31)28 (33)

    		Bupropion13 (8.0)8 (10)5 (6)

    		Varenicline15 (9.3)7 (9)8 (10)

    		Individual cessation counseling52 (32.1)25 (32)27 (32)

    		Group cessation counseling25 (15.4)10 (13)15 (18)

    		Cessation counseling and medication35 (21.6)17 (22)18 (231)

    		Started any treatment82 (50.6)34 (44)48 (57)
    Abstinence outcomes, n (%)

    		Verified abstinence at 6 monthsa7 (4.3)1 (1)6 (8)

    		Any quit attempt with ≥1 day abstinenceb61 (37.2)25 (30)36 (46)

    		Any quit attempt with ≥7 days abstinenceb24 (14.8)13 (15)11 (14)

    aCalculated from randomized sample.

    bCalculated from follow-up sample.

    Table 1 shows the number of participants who used each type of cessation treatment. Of the 63 participants who used any type of cessation treatment, some individuals used several types of medications, and some used group and individual behavioral cessation counseling. Of 162 participants, 21 (13.0%) had used at least one type of any verified cessation medication, 21 (13.0%) had used at least one type of any verified behavioral intervention, and the same number had used the recommended combination of both a behavioral and a medication intervention (21/162, 13.0%; these summary numbers are not shown in Table 1). A larger number of participants self-reported the use of treatment or had verified the use of treatment (also shown in Table 1). In bivariate logistic models, any verified treatment initiation was significantly predicted by older age (OR 1.03 [95% CI 1.00-1.06]; P=.05), higher levels of education (OR 1.18 [95% CI 1.02-1.37]; P=.02), and lower positive symptom scale scores (OR 0.87 [95% CI 0.79-0.95); P<.001). In the full multivariate model predicting cessation treatment utilization, older age, higher education, and lower level of positive symptoms, scores remained significant predictors of treatment initiation (see Table 2).

    Table 2. Predictors of treatment initiation after brief interventions.
    Demographic and smoking characteristicsUnivariate modelsaMultivariate modelsa
    ORb95% CIP valueOR95% CIP value
    Gender1.090.57-2.06.80N/AcN/AN/A
    Age1.031.00-1.06.051.031.00-1.07.05
    Education1.181.02-1.37.021.211.04-1.41.02
    Fagerström Score1.030.88-1.21.74N/AN/AN/A
    Cigarettes per day1.000.97-1.03.89N/AN/AN/A
    Cognitive function

    		TMd A time1.000.99-1.01.80N/AN/AN/A

    		TM B time1.001.00-1.00.30N/AN/AN/A

    		Color time0.990.96-1.02.53N/AN/AN/A

    		Word time1.000.96-1.03.83N/AN/AN/A

    		Interfere T0.990.98-1.01.24N/AN/AN/A

    		Hopkins Verbal Learning Test1.060.87-1.28.56N/AN/AN/A

    		 Continuous performance test0.890.76-1.03.12N/AN/AN/A

    		CognitionTotale0.970.61-1.55.91N/AN/AN/A
    Symptoms

    		BPRSf subscales


    		Positive0.870.79-0.95<.0010.870.80-0.96.01


    		Negative0.950.81-1.11.52N/AN/AN/A


    		Activation0.970.84-1.12.69N/AN/AN/A


    		Depression0.940.85-1.04.24N/AN/AN/A


    		Disorganized0.950.83-1.08.42N/AN/AN/A

    		BPRS total score0.970.94-1.00.06N/AN/AN/A

    		 PANASg positive1.010.98-1.05.50N/AN/AN/A

    		PANAS negative1.010.98-1.05.47N/AN/AN/A
    Intervention

    		Intervention group0.710.37-1.33.280.650.33-1.31.23

    aLogistic regression models.

    bOR: odds ratio.

    cN/A: not applicable.

    dTM: trial making.

    eOnly total cognition score was included in multivariate model.

    fBPRS: Brief Psychiatric Rating Scale.

    gPANAS: Positive and Negative Affect Schedule.

    Secondary Outcome

    Although more than one-third of participants (61/162, 37.7%) reported that they had tried to quit and 24 participants (24/162, 14.8%) reported at least 7 days of self-reported abstinence over the follow-up period, only 4.3% (7/162) of participants had biologically verified 7-day point prevalence abstinence at the 6-month assessment (1/78, 1%, in Let’s Talk About Smoking vs 6/84, 7%, in NCI Education; χ21=3.4; P=.07). Quit attempts and abstinence were not significantly different between intervention groups. In bivariate models predicting any self-reported abstinence during the follow-up period, greater level of education (beta=.214; SE 0.11; P=.04), greater positive affect (beta=.055; SE 0.03; P=.05), better overall cognitive functioning (composite score; beta=1.293; SE 0.42; P=.0002), and use of any cessation treatment (beta=1.112; SE 0.48; P=.02) significantly predicted abstinence (see Table 3). Better performance on most of the individual cognition scale scores also predicted self-reported abstinence. In adjusted multivariate models predicting days of abstinence, greater cognitive ability composite score and engagement in cessation treatment significantly predicted days of abstinence (see Table 3).

    Table 3. Predictors of abstinence after brief interventions.
    Demographic and clinical characteristicsUnivariate modelsaMultivariate modelsa
    EstbSEP valueEstSEP value
    Gender−0.1550.51.80N/AcN/AN/A
    Age0.0010.02.96N/AN/AN/A
    Education0.2140.11.040.1100.09.22
    Fagerström−0.0930.13.50N/AN/AN/A
    Cigarettes per day−0.0250.02.20N/AN/AN/A
    Cognitive function

    		TMd A time−0.0240.01.02N/AN/AN/A

    		TM B time−0.0030.00.06N/AN/AN/A

    		Color time−0.0560.02.005N/AN/AN/A

    		Word time−0.0560.03.04N/AN/AN/A

    		Interfere T−0.0200.01.05N/AN/AN/A

    		Hopkins Verbal Learning Test0.1660.19.40N/AN/AN/A

    		Continuous performance test0.2560.11.02N/AN/AN/A

    		CognitionTotale1.2930.42.0021.4710.47.002
    Symptoms

    		BPRSf subscales 
    		 

    		 


    		Positive−0.0110.07.90N/AN/AN/A


    		Negative−0.0910.13.50N/AN/AN/A


    		Activation0.0310.09.70N/AN/AN/A


    		Depression0.0570.08.50N/AN/AN/A


    		Disorganized−0.0160.10.90N/AN/AN/A

    		BPRS total score0.0150.02.50N/AN/AN/A

    		PANASg positive0.0550.03.050.0040.03.91

    		PANAS negative0.0090.03.80N/AN/AN/A
    Intervention and cessation treatment

    		Intervention group−0.0930.48.850.1550.46.74

    		Engaged in cessation treatment1.1120.48.021.4270.47.003

    aNegative binomial models.

    bEst: estimate.

    cN/A: not applicable.

    dTM: trial making.

    eOnly total cognition score was included in multivariate model.

    fBPRS: Brief Psychiatric Rating Scale.

    gPANAS: Positive and Negative Affect Scale.

    Intervention Usability and Satisfaction

    Usability and satisfaction mean summary index scores were significantly higher among participants assigned to Let’s Talk About Smoking compared with those assigned to NCI Education (8.9 [SD 1.3] vs 8.3 [SD 2.1]; t120.7=2.0; P=.045). Most participants (95.38% of Let’s Talk About Smoking users vs 83.1% of NCI Education users) reported that they were satisfied or very satisfied with the intervention. All participants completed the intervention to which they were assigned; no adverse events were reported during the use of the interventions. Approximately 97% of both groups said they would recommend their respective intervention to a friend.


    Principal Findings

    To our knowledge, this is the first randomized trial testing an interactive, multimedia digital motivational intervention to a static digital educational intervention for motivating smokers with schizophrenia to try to quit smoking using evidence-based cessation treatment. Contrary to our hypothesis, smokers with schizophrenia assigned to the interactive intervention were not more likely to initiate cessation treatment. However, these brief, digital interventions led to rates of treatment engagement consistent with studies of earlier versions of Let’s Talk About Smoking [62-64] and consistent with in-person motivational interviewing, in which 28% to 32.7% of smokers with schizophrenia and bipolar disorder attended an initial treatment appointment [28,29]. Similar to other studies of digital tools for people with schizophrenia and other SMIs [65,66], this study suggests that carefully designed, automated, digital interventions are feasible and acceptable among people with schizophrenia. Such tools could be used to engage smokers with schizophrenia into quit attempts using evidence-based smoking cessation treatment, potentially reducing demands on clinicians and clinics serving this population.

    Although both interventions were rated highly, the interactive, multimedia intervention was significantly more appealing than the static educational intervention. In a previous study, young adults with SMI rated the video content of Let’s Talk About Smoking the highest among the various types of content [67]. In nonstudy environments, future uptake of digital interventions might be most successful with a multimedia approach, including video compared with text-only interventions such as NCI Education.

    The computerized NCI Education performed numerically but not statistically significantly better than Let’s Talk About Smoking in this study, and numerically better than in a previous study of a paper pamphlet (15% initiated treatment) [63] and in-person interactive education (20.4% initiated treatment) [28]. The outcomes with NCI Education were likely facilitated by design features that facilitated comprehension and cognitive processing, including high contrast text with large font; audio in addition to text; presentation of a single concept per page; and sequential, linear formatting of the information. All these design features were also used in the interactive, multimedia intervention. Although video media is very appealing to users, this study indicates that it does not provide an advantage over text-only interventions within a research context.

    In this study, the use of any behavioral and pharmacologic cessation treatment following the study interventions significantly predicted abstinence, confirming that motivational and educational interventions should be followed by combined pharmacologic and behavioral interventions [22,24] in order for smokers with schizophrenia to achieve abstinence. Rates of biologically verified abstinence were consistent with what would be expected, given the types of cessation treatment used by the 61 participants who initiated treatment (7/61, 11% of abstinence). For example, 6 months after initiating treatment with a 3-month trial of bupropion, 4% of smokers with schizophrenia were abstinent [68]. Providing more Web-based motivational content for cessation and treatment utilization over repeated sessions and educating the clinicians to encourage and provide combined behavioral interventions and pharmacotherapy may improve utilization of the most effective combinations of treatments. Many community mental health centers do not include cessation treatment in their service array; thus, external services may be needed.

    Achieving abstinence is a challenging task requiring multiple cognitive functions. Better performance on our battery of tests assessing aspects of prefrontal functioning, such as cognitive flexibility and inhibitory control, significantly predicted abstinence over the 6-month follow-up, although participants initiated treatment and attempted to quit smoking regardless of the level of cognitive functioning, similar to our previous study [35]. Consistent with the abstinence finding here, previous studies have shown that lower scores on attention [55,69,70], information processing [70], and inhibitory control [71] were associated with worse cessation outcomes in smokers with schizophrenia, although not all studies are consistent with these findings. Although we did not measure working memory, other studies have also shown that working memory was associated with abstinence outcomes [70,71]. Attention, concentration, memory, working memory, and inhibitory control are arguably needed to learn smoking cessation skills and to use them while inhibiting the urge to smoke. Cognitive remediation interventions have been shown to improve cognition and functional outcomes among people with SMI who are receiving psychosocial interventions [72]. One promising initial study of cognitive remediation added to addiction treatment enhanced substance abuse outcomes among people with schizophrenia [73]. Cognitive remediation delivered with smoking cessation treatment has not been tested among smokers with schizophrenia.

    These results among middle-aged smokers with schizophrenia contrast with our previous work among young adults with SMIs [74]. In young adult smokers with SMI, the use of a similar digital intervention resulted in greater numbers of quit attempts and a greater proportion of people with biologically verified abstinence but less use of cessation treatment in the 3 months following the intervention [67].

    Several study limitations should be mentioned. First, this study used an active, computerized control condition; thus, we were unable to determine the level of advantage these interventions provide over usual care, such as doctor’s advice. Second, we were not able to obtain detailed information about the frequency and intensity of the community-delivered cessation medication and behavioral interventions, which would have facilitated a better understanding of our secondary abstinence outcome. Finally, study participants were recruited from three large community clinics in three states and included smokers with schizophrenia from several racial and ethnic groups, yet they may not be representative of all smokers with schizophrenia in the United States or other countries.

    Conclusions

    The interactive, multimedia, digital intervention was not more effective than a static digital intervention tailored to reduce cognitive load among smokers with schizophrenia. Both brief digital interventions garnered results similar to those found in previous studies of in-person motivational interventions among smokers with SMIs. Technology-delivered tobacco treatments have the promise to expand access in this high need population with high rates of smoking in clinics with longstanding workforce challenges but must be developed with user input and tested for efficacy, address data safety and privacy, and eventually integrate with electronic medical records and data systems [75]. Technology-delivered tobacco treatments could provide brief or long-term cessation skills training and cessation support, which could augment or replace in-person interventions for this population, as has been shown to be effective for the treatment of addiction in the general population [76]. Further research is warranted to evaluate efficacy and implementation strategies for digital interventions for smokers with schizophrenia and other SMIs.

    Acknowledgments

    The authors gratefully acknowledge the support of the study participants, the service providers at the participating agency’s programs, and the research departments at these agencies for their contributions to this study. This work was supported by the NCI (grant #1R01CA168778-01A1 Revised).

    Conflicts of Interest

    During the study period, MB had funding from Alkermes to conduct research on medication treatment for schizophrenia and alcohol disorder. JW had grant funding from Pfizer. The remaining authors did not report potential conflicts of interest. The version of Let’s Talk About Smoking tested in this study is owned by the first author’s primary institution.

    Multimedia Appendix 1

    Baseline demographics and characteristics of 162 study participants.

    DOCX File , 43 KB
    Multimedia Appendix 2

    CONSORT-EHEALTH checklist (V 1.6.2).

    PDF File (Adobe PDF File), 105 KB
    1. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. J Am Med Assoc. 2000;284(20):2606-2610. [CrossRef] [Medline]
    2. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health. Dec 2010;100(12):2464-2472. [CrossRef] [Medline]
    3. Taghizadeh N, Vonk JM, Boezen HM. Lifetime smoking history and cause-specific mortality in a cohort study with 43 years of follow-up. PLoS One. 2016;11(4):e0153310. [FREE Full text] [CrossRef] [Medline]
    4. Robiner WN. The mental health professions: workforce supply and demand, issues, and challenges. Clin Psychol Rev. Sep 2006;26(5):600-625. [CrossRef] [Medline]
    5. Olfson M. Building the mental health workforce capacity needed to treat adults with serious mental illnesses. Health Aff (Millwood). Jun 1, 2016;35(6):983-990. [CrossRef] [Medline]
    6. Himelhoch S, Riddle J, Goldman HH. Barriers to implementing evidence-based smoking cessation practices in nine community mental health sites. Psychiatr Serv. Jan 1, 2014;65(1):75-80. [CrossRef] [Medline]
    7. Brown CH, Medoff D, Dickerson FB, Fang LJ, Lucksted A, Goldberg RW, et al. Factors influencing implementation of smoking cessation treatment within community mental health centers. J Dual Diagn. 2015;11(2):145-150. [FREE Full text] [CrossRef] [Medline]
    8. Brunette M, Achtyes E, Pratt S, Stilwell K, Opperman M, Guarino S, et al. Use of smartphones, computers and social media among people with SMI: Opportunity for intervention. Community Ment Health J. Aug 2019;55(6):973-978. [CrossRef] [Medline]
    9. Bucci S, Morris R, Berry K, Berry N, Haddock G, Barrowclough C, et al. Early psychosis service user views on digital technology: qualitative analysis. JMIR Ment Health. Oct 31, 2018;5(4):e10091. [FREE Full text] [CrossRef] [Medline]
    10. Berry N, Lobban F, Bucci S. A qualitative exploration of service user views about using digital health interventions for self-management in severe mental health problems. BMC Psychiatry. Jan 21, 2019;19(1):35. [FREE Full text] [CrossRef] [Medline]
    11. Rotondi AJ, Spring MR, Hanusa BH, Eack SM, Haas GL. Designing eHealth applications to reduce cognitive effort for persons with severe mental illness: page complexity, navigation simplicity, and comprehensibility. JMIR Hum Factors. Jan 5, 2017;4(1):e1. [FREE Full text] [CrossRef] [Medline]
    12. Rotondi AJ, Sinkule J, Haas GL, Spring MB, Litschge CM, Newhill CE, et al. Designing websites for persons with cognitive deficits: design and usability of a psychoeducational intervention for persons with severe mental illness. Psychol Serv. Aug 2007;4(3):202-224. [FREE Full text] [CrossRef] [Medline]
    13. Brunette MF, Ferron JC, Devitt T, Geiger P, Martin WM, Pratt S, et al. Do smoking cessation websites meet the needs of smokers with severe mental illnesses? Health Educ Res. Apr 2012;27(2):183-190. [FREE Full text] [CrossRef] [Medline]
    14. Ferron JC, Brunette MF, Geiger P, Marsch LA, Adachi-Mejia AM, Bartels SJ. Mobile phone apps for smoking cessation: quality and usability among smokers with psychosis. JMIR Hum Factors. Mar 3, 2017;4(1):e7. [FREE Full text] [CrossRef] [Medline]
    15. Ferron JC, Brunette MF, McHugo GJ, Devitt TS, Martin WM, Drake RE. Developing a quit smoking website that is usable by people with severe mental illnesses. Psychiatr Rehabil J. 2011;35(2):111-116. [CrossRef] [Medline]
    16. Brunette MF, Ferron JC, Gottlieb J, Devitt T, Rotondi A. Development and usability testing of a web-based smoking cessation treatment for smokers with schizophrenia. Internet Interv. May 2016;4:113-119. [FREE Full text] [CrossRef] [Medline]
    17. Vilardaga R, Rizo J, Palenski P, Mannelli P, Oliver JA, McClernon FJ. Pilot randomized controlled trial of a novel smoking cessation app designed for individuals with co-occurring tobacco dependence and serious mental illness. Nicotine Tob Res. Oct 31, 2019. [CrossRef] [Medline]
    18. Klein P, Lawn S, Tsourtos G, van Agteren J. Tailoring of a Smartphone Smoking Cessation App (Kick.it) for Serious Mental Illness Populations: Qualitative Study. JMIR Hum Factors. Sep 3, 2019;6(3):e14023. [FREE Full text] [CrossRef] [Medline]
    19. Wilson SM, Thompson AC, Currence ED, Thomas SP, Dedert EA, Kirby AC, et al. Patient-informed treatment development of behavioral smoking cessation for people with schizophrenia. Behav Ther. Mar 2019;50(2):395-409. [CrossRef] [Medline]
    20. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. Jun 18, 2016;387(10037):2507-2520. [CrossRef] [Medline]
    21. Evins AE, Benowitz NL, West R, Russ C, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES trial. J Clin Psychopharmacol. 2019;39(2):108-116. [CrossRef] [Medline]
    22. Tidey JW, Miller ME. Smoking cessation and reduction in people with chronic mental illness. Br Med J. Sep 21, 2015;351:h4065. [FREE Full text] [CrossRef] [Medline]
    23. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. J Am Med Assoc. Jan 8, 2014;311(2):193-194. [CrossRef] [Medline]
    24. Evins AE, Cather C, Laffer A. Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harv Rev Psychiatry. 2015;23(2):90-98. [FREE Full text] [CrossRef] [Medline]
    25. Nawaz S, Frounfelker R, Ferron JC, Carpenter-Song EA, Davis K, Brunette MF. Smoking and Quitting Beliefs, Attitudes, and Behaviors Among Smokers With Severe Mental Illness From Three Race/Ethnicity Groups. J Dual Diagn. 2012;8(3):180-187. [CrossRef]
    26. Morris CD, Waxmonsky JA, May MG, Giese AA. What do persons with mental illnesses need to quit smoking? Mental health consumer and provider perspectives. Psychiatr Rehabil J. 2009;32(4):276-284. [CrossRef] [Medline]
    27. Lucksted A, McGuire C, Postrado L, Kreyenbuhl J, Dixon LB. Specifying cigarette smoking and quitting among people with serious mental illness. Am J Addict. 2004;13(2):128-138. [CrossRef] [Medline]
    28. Steinberg ML, Williams JM, Stahl NF, Budsock PD, Cooperman NA. An adaptation of motivational interviewing increases quit attempts in smokers with serious mental illness. Nicotine Tob Res. Mar 2016;18(3):243-250. [FREE Full text] [CrossRef] [Medline]
    29. Steinberg ML, Ziedonis DM, Krejci JA, Brandon TH. Motivational interviewing with personalized feedback: a brief intervention for motivating smokers with schizophrenia to seek treatment for tobacco dependence. J Consult Clin Psychol. Aug 2004;72(4):723-728. [CrossRef] [Medline]
    30. Cather C. A randomized controlled trial of motivational interviewing compared to psychoeducation for smoking pre-contemplators with severe mental illness. in Society for Research on Nicotine and Tobacco. Baltimore. 2010.
    31. Williams JM, Ziedonis DM, Vreeland B, Speelman-Edwards N, Zechner MR, Williams MT, et al. A wellness approach to addressing tobacco in mental health settings: learning about healthy living. Am J Psych Rehabil. 2009;12(4):352-369. [CrossRef]
    32. Shern DL, Wilson NZ, Coen AS, Patrick DC, Foster M, Bartsch DA, et al. Client outcomes II: Longitudinal client data from the Colorado treatment outcome study. Milbank Q. 1994;72(1):123-148. [CrossRef] [Medline]
    33. Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. Br Med J. Jul 7, 2007;335(7609):24-27. [FREE Full text] [CrossRef] [Medline]
    34. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. New York City, New York. Guilford Publications; 2002.
    35. Ferron JC, Brunette MF, McGurk SR, Xie H, Frounfelker R, Cook JA, et al. Do symptoms and cognitive problems affect the use and efficacy of a web-based decision support system for smokers with serious mental illness? J Dual Diagn. 2012;8(4):315-325. [CrossRef]
    36. National Cancer Institute: Comprehensive Cancer Information. URL: https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/quit-smoking-pdq [accessed 2017-03-05]
    37. Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale - Expanded (BPRS-E) structure and arguments for a new version. J Psychiatr Res. Oct 2016;81:140-151. [CrossRef] [Medline]
    38. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-241. [CrossRef] [Medline]
    39. Weinberger AH, Reutenauer EL, Allen TM, Termine A, Vessicchio JC, Sacco KA, et al. Reliability of the Fagerström test for nicotine dependence, Minnesota nicotine withdrawal scale, and Tiffany questionnaire for smoking urges in smokers with and without schizophrenia. Drug Alcohol Depend. Jan 12, 2007;86(2-3):278-282. [CrossRef] [Medline]
    40. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. Sep 1991;86(9):1119-1127. [CrossRef] [Medline]
    41. Donovan RJ, Jones S, Holman CD, Corti B. Assessing the reliability of a stage of change scale. Health Educ Res. Jun 1998;13(2):285-291. [CrossRef] [Medline]
    42. Ryan RM, Plant RW, O'Malley S. Initial motivations for alcohol treatment: relations with patient characteristics, treatment involvement, and dropout. Addict Behav. 1995;20(3):279-297. [CrossRef] [Medline]
    43. Ferron JC, Elbogen EB, Swanson JW, Swartz MS, McHugo GJ. A conceptually based scale to measure consumers’ treatment motivation. Res Soc Work Prac. 2011;21(1):98-105. [CrossRef]
    44. Jarvis MJ, Russell MA, Saloojee Y. Expired air carbon monoxide: a simple breath test of tobacco smoke intake. Br Med J. Aug 16, 1980;281(6238):484-485. [FREE Full text] [CrossRef] [Medline]
    45. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. May 2002;4(2):149-159. [CrossRef] [Medline]
    46. Sobell LC, Sobell MB. Timeline Follow-Back: A technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, editors. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods. Totowa, NJ. Human Press; 1992:41-72.
    47. Sobell L, Sobell M. Alcohol Timeline Followback (TLFB) Users Manual. In: Alcohol Timeline Followback (TLFB) Users Manual. Toronto, Canada. Addiction Research Foundation; 1996.
    48. Brown R, Burgess ES, Sales SD, Whiteley JA, Evans DM, Miller IW. Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav. 1998;12(2):101-112. [CrossRef]
    49. Sacks JA, Drake RE, Williams VF, Banks SM, Herrell JM. Utility of the Time-Line Follow-Back to assess substance use among homeless adults. J Nerv Ment Dis. Mar 2003;191(3):145-153. [CrossRef] [Medline]
    50. Davis FD. Perceived usefulness, perceived ease of use, and user acceptance of information technology. Manag Inf Syst Q. 1989;13(3):319-340. [CrossRef]
    51. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. Nov 1988;26(2):223-238. [CrossRef] [Medline]
    52. Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological Assessment. Third Edition. New York City, New York. Oxford University Press; 1995.
    53. Benedict R. Psychological Assessment Resources. URL: https://www.parinc.com/Products/Pkey/30 [accessed 2019-12-24]
    54. Benton A, Hamsher K, Sivan AB. Psychological Assessment Resources. URL: https://www.parinc.com/Products/Pkey/222 [accessed 2019-12-24]
    55. Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, et al. Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry. Nov 2008;69(11):1743-1750. [FREE Full text] [CrossRef] [Medline]
    56. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. Feb 2008;33(3):480-490. [FREE Full text] [CrossRef] [Medline]
    57. Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. Neuropsychol Rev. Sep 2007;17(3):259-273. [CrossRef] [Medline]
    58. Kramer JH, Delis DC, Kaplan E. Delis-Kaplan Executive Function System (D-KEFS) - Examiner's Manual. San Antonio, TX. The Psychological Corporation; 2001.
    59. Wilkinson G, Robertson G, Lutz F. Wide Range Achievement Test 4 Professional Manual. Odessa, Florida, United States. Psychological Assessment Resources; 2006.
    60. Harvey PD, Moriarty PJ, Friedman JI, White L, Parrella M, Mohs RC, et al. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biol Psychiatry. Jun 1, 2000;47(11):962-968. [CrossRef] [Medline]
    61. Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. New York City, New York. J Wiley and Sons; 1989.
    62. Brunette MF, Ferron JC, McHugo GJ, Davis KE, Devitt TS, Wilkness SM, et al. An electronic decision support system to motivate people with severe mental illnesses to quit smoking. Psychiatr Serv. Apr 2011;62(4):360-366. [CrossRef] [Medline]
    63. Brunette MF, Ferron JC, Drake RE, Devitt TS, Geiger PT, McHugo GJ, et al. Carbon monoxide feedback in a motivational decision support system for nicotine dependence among smokers with severe mental illnesses. J Subst Abuse Treat. Oct 2013;45(4):319-324. [CrossRef] [Medline]
    64. Brunette MF, Pratt SI, Bartels SJ, Scherer EA, Sigmon SC, Ferron JC, et al. Randomized trial of interventions for smoking cessation among medicaid beneficiaries with mental illness. Psychiatr Serv. Mar 1, 2018;69(3):274-280. [CrossRef] [Medline]
    65. Ben-Zeev D, Brian RM, Jonathan G, Razzano L, Pashka N, Carpenter-Song E, et al. Mobile health (mHealth) versus clinic-based group intervention for people with serious mental illness: a randomized controlled trial. Psychiatr Serv. Sep 1, 2018;69(9):978-985. [CrossRef] [Medline]
    66. Depp C, Perivoliotis D, Holden J, Dorr J, Granholm EL. Single-session mobile-augmented intervention in serious mental illness: a three-arm randomized controlled trial. Schizophr Bull. Jun 18, 2019;45(4):752-762. [CrossRef] [Medline]
    67. Brunette MF, Ferron JC, Robinson D, Coletti D, Geiger P, Devitt T, et al. Brief web-based interventions for young adult smokers with severe mental illnesses: a randomized, controlled pilot study. Nicotine Tob Res. Sep 4, 2018;20(10):1206-1214. [FREE Full text] [CrossRef] [Medline]
    68. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. Jun 2005;25(3):218-225. [CrossRef] [Medline]
    69. Schuster RM, Cather C, Pachas GN, Zhang H, Cieslak KM, Hoeppner SS, et al. Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. Addict Behav. Aug 2017;71:89-95. [FREE Full text] [CrossRef] [Medline]
    70. Moss TG, Sacco KA, Allen TM, Weinberger AH, Vessicchio JC, George TP. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. Sep 1, 2009;104(1-2):94-99. [FREE Full text] [CrossRef] [Medline]
    71. Dolan SL, Sacco KA, Termine A, Seyal AA, Dudas MM, Vessicchio JC, et al. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res. Oct 1, 2004;70(2-3):263-275. [CrossRef] [Medline]
    72. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. May 2011;168(5):472-485. [CrossRef] [Medline]
    73. Eack SM, Hogarty SS, Greenwald DP, Litschge MY, McKnight SA, Bangalore SS, et al. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial. Schizophr Res. Feb 2015;161(2-3):478-483. [FREE Full text] [CrossRef] [Medline]
    74. Brunette MF, Feiron JC, Aschbrenner K, Colctti D, Devitt T, Greene MA, et al. Characteristics and predictors of intention to use cessation treatment among smokers with schizophrenia: Young adults compared to older adults. J Subst Abus Alcohol. 2017;5(1):pii: 1055. [FREE Full text] [Medline]
    75. Torous J, Andersson G, Bertagnoli A, Christensen H, Cuijpers P, Firth J, et al. Towards a consensus around standards for smartphone apps and digital mental health. World Psychiatry. Feb 2019;18(1):97-98. [FREE Full text] [CrossRef] [Medline]
    76. Marsch LA, Dallery J. Advances in the psychosocial treatment of addiction: the role of technology in the delivery of evidence-based psychosocial treatment. Psychiatr Clin North Am. Jun 2012;35(2):481-493. [FREE Full text] [CrossRef] [Medline]

    ‎
    BPRS: Brief Psychiatric Rating Scale
    Est: estimate
    NCI: National Cancer Institute
    OR: odds ratio
    SMI: serious mental illness

    Edited by D Fulford; submitted 21.10.19; peer-reviewed by E Achtyes, H Haydon, M Gaman, E Camacho; comments to author 01.12.19; revised version received 02.12.19; accepted 05.12.19; published 10.02.20.

    Copyright

    ©Mary F F Brunette, Joelle C Ferron, Susan R McGurk, Jill M Williams, Amy Harrington, Timothy Devitt, Haiyi Xie. Originally published in JMIR Mental Health (http://mental.jmir.org), 10.02.2020.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Mental Health, is properly cited. The complete bibliographic information, a link to the original publication on http://mental.jmir.org/, as well as this copyright and license information must be included.